Blanco, EstherTorres, Elisade León, PatriciaForner, Mar, 1980-Bustos, María J.Hammer, Sabine E.Sobrino, FranciscoAndreu Martínez, DavidDefaus, Sira2025-10-272025-10-272025Blanco E, Torres E, de León P, Forner M, Bustos MJ, Hammer SE, Sobrino F, Andreu D, Defaus S. Single dose of foot-and-mouth disease peptide vaccine fully protects swine and achieves intraserotype crossed neutralization. NPJ vaccines. 2025 Oct 6;10(1):216. DOI: 10.1038/s41541-025-01274-y2059-0105http://hdl.handle.net/10230/71662Foot-and-mouth disease virus (FMDV) poses a persistent threat to the livestock sector, urging a need for safer and more effective vaccines. As traditional control approaches relying on inactivated virus vaccines face limitations, exploring subunit vaccine strategies such as those based on synthetic peptides represents an attractive alternative, compliant with DIVA vaccine requirements. We previously reported that dendrimer structures combining virus-specific B- and T-cell epitopes-referred to as B2T-conferred solid protection against type-O FMDV in swine. More recently, we designed a synthetic strategy with broad application prospects, assembling peptides into a modular dendrimer platform named B2T-TB2, a dimeric version of the preceding construct, harboring up to six immunologically relevant epitopes. In this study, we demonstrate that a single low dose of this multiepitopic vaccine induces in swine a fast and robust neutralizing response covering a broad antigenic spectrum and confers full protection, portraying B2T-TB2 as a promising FMDV emergency vaccine.application/pdfeng© The Author(s) 2025. Open Access This article is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License, which permits any non-commercial use, sharing, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if you modified the licensed material. You do not have permission under this licence to share adapted material derived from this article or parts of it. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by-nc-nd/4.0/.info:eu-repo/semantics/article2025-10-27http://dx.doi.org/10.1038/s41541-025-01274-yPeptide vaccinesViral infectioninfo:eu-repo/semantics/openAccess